A modified delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia
- Stanley N. Caroff(corresponding author),
- Leslie Citrome,
- Jonathan Meyer,
- Martha Sajatovic,
- Joseph F. Goldberg,
- Rakesh Jain
- University of Pennsylvania,
- New York Medical College,
- University of California at San Diego,
- Case Western Reserve University,
- Icahn School of Medicine at Mount Sinai,
- Texas Tech University Health Sciences Center
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewSustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>Objective: A nominal group process followed by a modified Delphi method was used to survey expert opinions on best practices for tardive dyskinesia (TD) screening, diagnosis, and treatment and to identify areas lacking in clinical evidence. Participants: A steering committee of 11 TD experts met in nominal group format to prioritize questions to be addressed and identify core bibliographic materials and criteria for survey panelists. Of 60 invited experts, 29 (23 psychiatrists and 6 neurologists) agreed to participate. Evidence: A targeted literature search of PubMed (search term: tardive dyskinesia) and recommendations of the steering committee were used to generate core bibliographic material. Inclusion criteria were as follows: (1) review articles, metaanalyses, guidelines, or clinical trials; (2) publication in English between 2007 and 2017; (3) > 3 pages in length; and (4) publication in key clinical journals with impact factors ≥ 2.0. Of 29 references that met these criteria, 18 achieved a score ≥ 5 (calculated as the number of steering committee votes multiplied by journal impact factor and number of citations divided by years since publication) and were included. Consensus Process: Two survey rounds were conducted anonymously through electronic media from November 2017 to January 2018; responses were collected, collated, and analyzed. Respondent agreement was defined a priori as unanimous (100%), consensus (75%-99%), or majority (50%- 74%). For questions using a 5-point Likert scale, agreement was based on percentage of respondents choosing ≥ 4 ("agree completely" or "agree"). Round 1 survey included questions on TD screening, diagnosis, and treatment. Round 2 questions were refined per panelist feedback and excluded Round 1 questions with < 25% agreement and > 75% agreement (unless feedback suggested further investigation). Conclusions: Consensus was reached that (1) a brief, clinical assessment for TD should be performed at every clinical encounter in patients taking antipsychotics; (2) even mild movements in 1 body area may represent possible TD; (3) management requires an overall evaluation of treatment, including reassessment of antipsychotics and anticholinergics as well as consideration of vesicular monoamine transporter 2 (VMAT2) inhibitors; and (4) informed discussions with patients/caregivers are essential.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Article number
19cs12983Journal (Volume, Issue Number)
Journal of Clinical Psychiatry (Volume 81, Issue 2)Publication milestones
- Published - 04/01/2020
Publication status
Published - 04/01/2020
ISSN
0160-6689Publication IDs
- Scopus: 85078689127
- PubMed: 31995677
Publication metrics
Metrics
SciVal
FWCI
1.54
SciVal
Author count
12
SciVal
citations
3
SciVal
Paper percentile
84
Fractional count
1
Fractional count
0.08
Fractional count
11
Fractional count
0.92
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Captures
48
Mentions
4
Usage
16
Citation count
35
Funding Details
Submitted: July 3, 2019; accepted November 25, 2019. Published online: January 28, 2020. Potential conflicts of interest: Dr Caroff has served as a consultant to Neurocrine Biosciences Inc, Teva, Osmotica, and DisperSol Technologies and has received research support from Neurocrine Biosciences Inc. Dr Citrome has served as a consultant to Acadia, Alkermes, Allergan, Impel, Intra-Cellular Therapeutics, Janssen, Lundbeck, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva, and Vanda; has served as a speaker for Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva, and Vanda; owns stocks (small number of shares of common stock) of Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, and Pfizer; and receives royalties from Wiley (Editor-in-Chief, International Journal of Clinical Practice), UpToDate (reviewer), and Springer Healthcare (book). Dr Meyer has received speaking or advising fees from Acadia, Alkermes, Allergan, Arbor Scientia, Intra-Cellular Therapies, Neuroscience Education Institute, Neurocrine Biosciences, Otsuka, Sunovion, and Teva. Dr Sajatovic has received research support from the National Institutes of Health, Centers for Disease Control and Prevention, International Society for Bipolar Disorders, Janssen, Merck, Pfizer, Reinberger Foundation, Reuter Foundation, Alkermes, Otsuka, and the Woodruff Foundation; has been a consultant for Bracket, Neurocrine Biosciences, Inc, Otsuka, Pfizer, ProPhase, Health Analytics, and Supernus; has received royalties from Johns Hopkins University Press, Lexicomp, Oxford University Press, Springer Press, and UpToDate; and has participated in continuing medical education activities for the American Physician Institute, CMEology, Creative Educational Concepts, and MCM Education. Dr Goldberg has served as a speaker and/or advisor for Allergan, Neurocrine Biosciences, Otsuka, Sunovion, and Takeda. Dr Jain has received grant funding and/or honoraria for lectures and/or participation in advisory boards for Addrenex, Forest Laboratories (Allergan), Eli Lilly, Lundbeck, Merck, Neurocrine, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, and Takeda. Dr Lundt is an employee of Neurocrine Biosciences, Inc. Dr Lindenmayer is a consultant for Otsuka and Lundbeck and has received research support from Janssen, Alkermes, FORUM, Neurocrine, Avanir, Roche, Takeda, Intracellular, and Astellas. Dr McEvoy has received consulting fees, honoraria, and/or grants from Alkermes, Avanir, Boehringer Ingelheim, Neurocrine, Otsuka, and Teva. Dr McIntyre has received consulting fees from Neurocrine Biosciences and speaker/consultant fees from Lundbeck, Pfizer, AstraZeneca, Janssen Ortho, Sunovion, Takeda, Neurocrine, Otsuka, Allergan, Shire, Purdue, and Bristol-Myers Squibb and has received research grant support from Stanley Medical Research Institute, the National Natural Science Foundation of China, Canadian Institutes for Health Research, and
This study received financial support from Neurocrine Biosciences, Inc., San Diego, California
